Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Sarcoma 1Head & Neck 1Genitourinary 1

Conditions

Stomach Neoplasms 40Colorectal Neoplasms 9Adenocarcinoma 8Esophageal Neoplasms 7Carcinoma, Hepatocellular 7Neoplasms 5Colonic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Neoplasm Metastasis 4Rectal Neoplasms 3Liver Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Metastatic Gastric Adenocarcinoma 2Melanoma 2Cholangiocarcinoma 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma, Alveolar Soft Part 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms by Site 1Lymphoma, Mantle-Cell 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Liver Diseases 1Head and Neck Neoplasms 1HER2-positive Gastric Cancer 1

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Ramucirumab × Gastrointestinal × Clear all
NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Eli Lilly and Company

Phase 2 Active not recruiting
309 enrolled 22 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Eli Lilly and Company

Phase 1 Completed
175 enrolled 23 charts
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡